Network meta-analysis of progression free survival in the treatment of relapsed or refractory chronic lymphocytic leukemia.

被引：0
|
作者：
Chanan-Khan, Asher
Liu, Tom
Yang, Keri
Cohen, Aileen
Fahrbach, Kyle
Campbell, Joanna
Tang, Boxiong
机构：
[1] Mayo Clin, Jacksonville, FL USA
[2] BeiGene Inc, San Mateo, CA USA
[3] Evidera, Lexington, MA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2022年 / 40卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
19514
引用
收藏
页数：1
相关论文
共 50 条
  • [1] A network meta-analysis of progression free survival and overall survival in first-line treatment of chronic lymphocytic leukemia
    Ladyzynski, Piotr
    Molik, Maria
    Foltynski, Piotr
    CANCER TREATMENT REVIEWS, 2015, 41 (02) : 77 - 93
  • [2] Network meta-analysis of novel targeted therapies for relapsed/refractory chronic lymphocytic leukemia
    Monica, Magdalena
    Reczek, Monika
    Kawalec, Pawel
    THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2024, 16
  • [3] Economic burden of relapsed/refractory chronic lymphocytic leukemia.
    Guerin, Annie
    Ray, Saurabh
    Gauthier, Genevieve
    Hsu, Ling-I
    Zhdanava, Maryia
    Heroux, Julie
    Wu, Eric Qiong
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [4] Meta-Analysis of the Efficacy and Adverse Effects of Acalabrutinib in the Treatment of Relapsed/Refractory Chronic Lymphocytic Leukemia
    Park, Daniel
    Chan-Golston, Alec M.
    Akhtari, Mojtaba
    BLOOD, 2023, 142
  • [5] Comparative safety of novel targeted therapies in relapsed/refractory chronic lymphocytic leukemia: a network meta-analysis
    Monica, Magdalena
    Reczek, Monika
    Kawalec, Pawel
    THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2024, 16
  • [6] The Magnitude of Improvement in Progression-Free Survival with Targeted Therapy in Relapsed/Refractory Chronic Lymphocytic Leukemia Based on Genetic Risk: A Systematic Review and Meta-Analysis
    Molica, Stefano
    Giannarelli, Diana
    Mirabelli, Rosana
    Levato, Luciano
    Shanafelt, Tait D.
    BLOOD, 2018, 132
  • [7] Comparative efficacy of Bruton tyrosine kinase inhibitors in the treatment of relapsed/refractory chronic lymphocytic leukemia: A network meta-analysis (NMA)
    Shadman, Mazyar
    Brown, Jennifer R.
    Mohseninejad, Leyla
    Yang, Keri
    Burnett, Heather
    Neupane, Binod
    Williams, Rhys
    Lamanna, Nicole
    O'Brien, Susan M.
    Tedeschi, Alessandra
    Tam, Constantine S.
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [8] EFFICACY AND SAFETY OF VENETOCLAX plus RITUXIMAB IN THE TREATMENT OF RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA: RESULTS OF BAYESIAN NETWORK META-ANALYSIS
    Monica, M.
    Reczek, M.
    Kawalec, P.
    VALUE IN HEALTH, 2023, 26 (06) : S35 - S35
  • [9] Pentostatin with an alkylating agents in refractory or relapsed chronic lymphocytic leukemia.
    Jajeh, A
    Ali, S
    Abboud, W
    Hadad, L
    Zalzaleh, G
    BLOOD, 2002, 100 (11) : 366B - 366B
  • [10] The magnitude of improvement in progression-free survival with targeted therapy in relapsed/refractory chronic lymphocytic leukemia based on prognostic risk category: a systematic review and meta-analysis
    Molica, Stefano
    Giannarelli, Diana
    Mirabelli, Rosanna
    Levato, Luciano
    Shanafelt, Tait D.
    LEUKEMIA & LYMPHOMA, 2019, 60 (07) : 1644 - 1649
12345